

Arden and Greater East Midlands Commissioning Support Unit in association with Lincolnshire Clinical Commissioning Groups, Lincolnshire Community Health Services, United Lincolnshire Hospitals Trust and Lincolnshire Partnership Foundation Trust

Lincolnshire *PACE* Shorts

Summary of PACEF decisions from March 2016

For further details see *PACE Bulletin* Volume 10; Number 6 (May 2016)

SUMMARY OF PACEF DECISIONS: MARCH 2016 UPDATE

Device, Dressing or Drug	Indication(s)	Traffic Light and <i>Joint Formulary</i> Status
Beclometasone dipropionate 200 microgram/formoterol 6microgram per actuation (<i>Fostair 200/6 metered dose inhaler</i>) (Chiesi Ltd)	For the regular treatment of asthma in adults) where the use of a combination ICS/LABA is considered appropriate (i.e. in patients not adequately controlled with ICS and 'as needed' inhaled short-acting beta2-agonist or in patients already adequately controlled on both ICS and LABA).	GREEN Approved for inclusion in the <i>Lincolnshire Joint Formulary</i> .
Beclometasone dipropionate 200 microgram/formoterol 6microgram per actuation (<i>Fostair 200/6 NEXThaler</i>) (Chiesi Ltd)	For the regular treatment of asthma in adults where the use of a combination ICS/LABA is considered appropriate (i.e. in patients not adequately controlled with ICS and 'as needed' inhaled short-acting beta2-agonist or in patients already adequately controlled on both ICS and LABA).	GREEN Approved for inclusion in the <i>Lincolnshire Joint Formulary</i> .
Cinacalcet 30mg, 60mg and 90mg tablets (<i>Mimpara</i>) (Amgen)	For secondary hyperparathyroidism in patients with end-stage renal disease on dialysis , as part of a regimen including phosphate binders and /or vitamin D.	AMBER with shared care. Shared care guideline available. Included in the <i>Lincolnshire Joint Formulary</i> .
Eltrombopag 25mg and 50mg tablets (<i>Revolade</i>) (Novartis Pharmaceuticals UK Ltd)	For treating severe aplastic anaemia refractory to immunosuppressive therapy	RED-RED Not approved for inclusion in the <i>Lincolnshire Joint Formulary</i> .
Enzalutamide 40mg capsules (<i>Xtandi</i>) (Astellas Pharma Ltd)	For treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated	RED Approved for inclusion in the <i>Lincolnshire Joint Formulary</i> .
Nintedanib 100mg and 150mg capsules (<i>Ofev</i>) (Boehringer Ingelheim Limited)	For treating idiopathic pulmonary fibrosis	RED Likely to be prescribed within tertiary centres only. Approved for use within the <i>Lincolnshire Joint Formulary</i> .
Nivolumab 10mg/ml concentrate for solution for infusion (<i>Opdivo</i>) (Bristol-Myers Squibb Pharmaceutical Limited)	For treating advanced (unresectable or metastatic) melanoma	RED Approved for use within the <i>Lincolnshire Joint Formulary</i> .
Olaparib 50mg capsules (<i>Lynparza</i>) (AstraZeneca UK Ltd)	For maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum based chemotherapy	RED Approved for use within the <i>Lincolnshire Joint Formulary</i>
Panobinostat 10mg, 15mg and 20mg capsules (<i>Farydak</i>) (Novartis Pharmaceuticals UK Ltd)	For treating multiple myeloma after at least two previous treatments	RED Approved for inclusion in the <i>Lincolnshire Joint Formulary</i> .
Radium 223 dichloride (<i>Xofigo</i>) 1000 kBq/mL solution for injection.(Bayer)	For treating adults with	Designated RED for these indications.

	hormone-relapsed prostate cancer, symptomatic bone metastases and no known visceral metastases.	Approved for inclusion in the <i>Lincolnshire Joint Formulary</i> .
Ramucirumab 10mg/ml solution for infusion (<i>Cyramza</i>) (Eli Lilly and Company Ltd)	For treating advanced gastric cancer or gastro-oesophageal junction adenocarcinoma previously treated with chemotherapy	RED-RED Not approved for inclusion in the <i>Lincolnshire Joint Formulary</i> .
Salmeterol 50microgram/ fluticasone propionate 500 microgram per actuation dry powder inhaler (<i>AirFluSal Forspiro</i>) (Sandoz Ltd)	For the symptomatic treatment of adults with Chronic Obstructive Pulmonary Disease (COPD), specifically those with a FEV1 <60% predicted normal (pre-bronchodilator) and a history of repeated exacerbations who have significant symptoms despite regular bronchodilator therapy.	GREEN Approved for inclusion in the <i>Lincolnshire Joint Formulary</i> .
Trametinib 0.5mg and 2mg tablets (<i>Mekinist</i>) (Novartis Pharmaceuticals UK Ltd)	For use as monotherapy or in combination with dabrafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.	RED-RED Not approved for inclusion in the <i>Lincolnshire Joint Formulary</i>
Vortioxetine 5mg, 10mg and 20mg tablets (<i>Brintellix</i>) (Lundbeck Ltd)	For the treatment of major depressive episodes in adults.	Designation: AMBER without shared care. Third line. Approved for inclusion in the <i>Lincolnshire Joint Formulary</i>

RED-RED: This signifies that a product is **not recommended** for prescribing in **either** primary or secondary care. All new products are classified as RED-RED pending assessment by PACEF.

RED: This signifies that a product has been approved for use within secondary care, tertiary care or a primary care hosted specialist service only and **should not be routinely prescribed in primary care**. RED drugs may be used within ULHT or LPFT subject to approval for use within each Trust. ULHT and LPFT reserve the right to determine whether or not RED drugs will be used within their Trusts. RED classification does not automatically signify that a drug will be available within secondary/tertiary care.

AMBER: This signifies that a drug has been approved for use in primary care **subject to specialist initiation; a shared care guideline (SCG) may also be required**. The main purpose of the SCG will be to clearly define both specialist and GP responsibilities. Not all AMBER drugs that require SCGs are currently covered by formal documents; PACEF are working to rectify this.

GREEN: This signifies a product that is **approved for initiation in either primary or secondary care**.

This bulletin has been created specifically to convey details of decisions taken at the Prescribing and Clinical Effectiveness Forum (PACEF) to all stakeholders across the Lincolnshire Healthcare Community in both primary and secondary care. Back issues of the *PACE Bulletin* and *PACE Shorts* are available through the PACEF website (<http://lincolnshire-pacef.nhs.uk>); follow the commissioning link to PACEF. Electronic copies of the *PACE Bulletin* are circulated to a wide readership via email. If you are not currently on our distribution list and wish to receive regular copies of PACEF publications please contact Sandra France on sandra.france@ardengemcsu.nhs.uk.

Google searching can be a quick and effective way of finding back numbers of the *PACE Bulletin* relevant to a specific topic of interest. Searchers are advised to use the official version of the *Bulletin* available from the PACEF website rather than depend on a potentially unreliable draft or variant found through Google or an alternative search engine.

The *Lincolnshire Joint Formulary* is available on line and is fully searchable; it can be accessed at www.lincolnshirejointformulary.nhs.uk

THIS DOCUMENT IS INTENDED FOR USE BY NHS HEALTHCARE PROFESSIONALS ONLY AND CANNOT BE USED FOR COMMERCIAL OR MARKETING PURPOSES WITHOUT PERMISSION